Melissa D. Landis

6.2k citations
28 papers · 1.8k indexed · h-index 23

Melissa D. Landis

28 papers receiving 1.8k citations

Peers

Melissa D. Landis
Comparison fields: 5 of 106
  • Oncology 868
  • Cancer Research 393
  • Molecular Biology 940
  • Toxicology 34
  • Pharmacology 78
Replace Lacey E. Dobrolecki with:
Lacey E. Dobrolecki United States
Bhuvanesh Dave United States
Paolo Ubezio Italy
Marc‐Eric Halatsch Germany
Mårten Fryknäs Sweden
Béla Ózsvári United Kingdom
Chandra Bartholomeusz United States
Neil Vasan United States
John G. Moffat United States
J. Vázquez France
Melissa D. Landis relative to Lacey E. Dobrolecki United States Lacey E. Dobrolecki's profile →
Citations per field
00.5×1.6×
Lacey E. Dobrolecki · 1×
Citations per year

Countries citing papers authored by Melissa D. Landis

Since Specialization
Citations

This map shows the geographic impact of Melissa D. Landis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa D. Landis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa D. Landis more than expected).

Fields of papers citing papers by Melissa D. Landis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa D. Landis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa D. Landis. The network helps show where Melissa D. Landis may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Melissa D. Landis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Melissa D. Landis Line = papers co-authored together Melissa D. Landis links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 201649
2 201647
3 201530
4 2015175
5 2014137
6 201420
7 2013209
8 201336
9 201329
10 2012162
11 201253
12 201147
13 201062
14 200933
15 2008260
16 20078
17 200740
18 200624
19 200552
20 200227

About Melissa D. Landis

Melissa D. Landis is a scholar working on Oncology, Biomaterials and Cancer Research, having authored 28 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Cells and Metastasis (9 papers), Nanoparticle-Based Drug Delivery (5 papers), HER2/EGFR in Cancer Research (5 papers), Cancer Risks and Factors (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Cancer Genomics and Diagnostics (3 papers), Cancer-related Molecular Pathways (3 papers) and Cancer Mechanisms and Therapy (2 papers). The work is most often cited by research in Oncology (868 citations), Cancer Research (393 citations) and Molecular Biology (940 citations). Melissa D. Landis has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Jenny C. Chang, Helen Wong, Dong Soon Choi, Bhuvanesh Dave, Michael T. Lewis, Ruth A. Keri, Lacey E. Dobrolecki, Angel Rodriguez, Darcie D. Seachrist and Susan G. Hilsenbeck. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026